ERK1/2 inhibitor 6
ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1) [1].
Product Specifications
CAS Number
2634816-13-8
UNSPSC
12352005
Target
ERK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/erk1-2-inhibitor-6.html
Solubility
10 mM in DMSO
Smiles
O=C1C2=CC(C3=NC(NC4CCOCC4)=NC=C3Cl)=CN2N=CN1[C@H](C)C(N[C@@H](C5=CC(OC)=CC(F)=C5)CO)=O
Molecular Formula
C27H29ClFN7O5
Molecular Weight
586.01
References & Citations
[1]Jin Li, et al. Erk1/2 protein kinase inhibitors and their uses. Patent WO2021063335A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD81 / TAPA-1 (1.3.3.22), CF405S conjugate, 0.1mg/mL
CD45 / LCA (2B11 + PD7/26), CF568 conjugate, 0.1mg/mL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
